TY - JOUR
T1 - Docetaxel and exisulind in hormone-refractory prostate cancer
AU - Ryan, Christopher W.
AU - Stadler, Walter M.
AU - Vogelzang, Nicholas J.
N1 - Funding Information:
From the Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL. Supported in part by Aventis Nwmaceuticals Pathways, Inc. Dr Ryan h received research support and honoraria from Awen-tis Phavnaceuticals Inc. Dr Vogekang has sewed as a consultant to Aventis Pharmaceuticals Inc and Cell Pathways, Inc. Awentis Pharmaceuticals Inc has donated support to the Uniueysity of Chicago Cancer Research Center, of which Dr Vogelrang is the director. Address reprint requests to Christopher W. Ryan, MD, University of Chicago, Section of Hematology/Oncology, 5841 S Maryland Ave., Chicago, IL 60637. Copyright 0 2001 by W.B. Saunders Company 0093-7754/01/2804.1510$35.00/0
PY - 2001
Y1 - 2001
N2 - Single-agent docetaxel has been shown to produce a significant decrease in prostate-specific antigen (PSA) levels among patients with hormone-refractory prostate cancer (HRPC). A recent study also showed that exisulind, a sulfone metabolite of the nonsteroidal anti-inflammatory drug sulindac, lengthens the median PSA doubling time in men who had increasing PSA levels after radical prostatectomy. Furthermore, exisulind has shown significant antineoplastic activity in prostate cancer cell lines in vitro and in nude mouse xenograft models. Because preclinical studies have suggested synergistic interactions between docetaxel and exisulind, a phase I/II clinical trial combining these agents has been initiated in patients with HRPC. The primary objective of this study is to determine PSA response and measurable disease response rate of the combination therapy; secondary objectives include toxicity assessment and determination of time to disease progression, duration of response, and overall survival. Accrual is ongoing.
AB - Single-agent docetaxel has been shown to produce a significant decrease in prostate-specific antigen (PSA) levels among patients with hormone-refractory prostate cancer (HRPC). A recent study also showed that exisulind, a sulfone metabolite of the nonsteroidal anti-inflammatory drug sulindac, lengthens the median PSA doubling time in men who had increasing PSA levels after radical prostatectomy. Furthermore, exisulind has shown significant antineoplastic activity in prostate cancer cell lines in vitro and in nude mouse xenograft models. Because preclinical studies have suggested synergistic interactions between docetaxel and exisulind, a phase I/II clinical trial combining these agents has been initiated in patients with HRPC. The primary objective of this study is to determine PSA response and measurable disease response rate of the combination therapy; secondary objectives include toxicity assessment and determination of time to disease progression, duration of response, and overall survival. Accrual is ongoing.
UR - http://www.scopus.com/inward/record.url?scp=0034794830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034794830&partnerID=8YFLogxK
U2 - 10.1053/sonc.2001.26903
DO - 10.1053/sonc.2001.26903
M3 - Article
C2 - 11685730
AN - SCOPUS:0034794830
SN - 0093-7754
VL - 28
SP - 56
EP - 61
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - 4 SUPPL. 15
ER -